New Stock News | Dayi Group's Hong Kong IPO Prospectus Invalidated

Xi'an Deyi Group Co., Ltd. (abbreviated as Deyi Group) submitted its Hong Kong stock prospectus on April 28, which will expire on October 28 after 6 months. During the submission, CITIC Securities International, Pudong Development Bank International, and CMBC CAPITAL served as its joint sponsors. According to the prospectus, Deyi Group is a global leader and pioneer in innovative radiotherapy solutions, dedicated to building a new generation of intelligent radiotherapy ecosystems. Since its establishment in 2011, the group has developed a comprehensive treatment matrix, which includes multiple solutions that have been approved and/or are in development stages. The group's core product, CybeRay, is the world's first real-time image-guided gamma radiotherapy system, which received approval from the U.S. Food and Drug Administration ("FDA") in March 2021 and from the National Medical Products Administration of China ("NMPA") in July 2022, and is currently in the research and development stage for expanding indications. The group also has a flagship product, TaiChiRT Pro, which is the world's first integrated radiotherapy system for X/gamma rays to receive breakthrough medical device designation from the FDA